Acetyl tetrapeptide-5
Cosmetic ingredientCosmetic signal peptide
Also known as: Eyeseryl, Ac-Beta-Ala-His-Ser-His-OH, Acetyl Tetrapeptide, Depuffin, Ac-betaAla-His-Ser-His, Acetyl Tetrapeptide-5/eyeseryl
Very thin human evidence
- Regulatory standing. Cosmetic ingredient, not regulated as a drug
- Animal / preclinical only. Evidence is largely animal or in-vitro
- No registered human trials. Nothing registered on ClinicalTrials.gov
- 1 cited source. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Acetyl tetrapeptide-5, sold under the trade name Eyeseryl, is a short synthetic peptide used as an ingredient in cosmetic eye creams and serums. It is marketed as reducing under-eye puffiness, with proposed mechanisms such as limiting fluid buildup, improving local microcirculation, and reducing glycation of skin proteins.
What the evidence shows
It is regulated as a cosmetic ingredient, is not FDA-approved for any use, and has no registered human clinical trials. The only support comes from very limited published literature and largely manufacturer-sponsored data, so any effect on puffiness in people is not established.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Sources
- PubChem compound record (CID 11620163)
- Registered trials on ClinicalTrials.gov
- Published papers on Europe PMC
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.